Skip to main content

Inserm U1096 EnVI


Our cardiovascular research group was founded in the early 1990s as an University research group and received its first Inserm label (EMI 9920), followed by creation of an Inserm Unit in 2004, under the direction of Pr. Christian THUILLEZ, Professor (PU-PH) in Pharmacology. The Unit was recreated in 2012 (Dir Vincent RICHARD, PU-PH), and again recreated in 2022 (Dir Jeremy BELLIEN, PU-PH).

Our research unit participates as Partners in several FHU and RHU networks lead by the Cardiology Department at Rouen Normandy University Hospital (Remod-VHF, RHU STOP-AS, and FHU CARNAVAL). We also lead or participate in national and international networks of excellence (ANR, ERA-CVD, Normandy Chair of Excellence, etc). Our solid and well-recognized research expertise, notably in preclinical functional evaluations, has resulted in opportunities to collaborate with leading national and international companies of the biopharmaceutical industry. Our innovative research has led to several patents and high impact publications on the topic of new pharmacological or biological treatments for cardiovascular diseases.

The research performed in the Inserm U1096 Unit in Rouen, concerns evaluation of the mechanisms behind and novel treatments of cardiovascular diseases, focusing on vascular protection, treatment of aortic stenosis, and improvement of cardiac contractile function. This research is transversal, and performed both in experimental models and in human.

Vascular research: Protection of vascular endothelial cells in the context of cardiovascular risk factors or cardiovascular diseases (hypertension, diabetes, myocardial infarction, heart failure etc), notably within the framework of the ANR project PHASM.
Valvular research:  Search for new preventive treatments of aortic stenosis, and improvement of current treatments focusing especially on transcutaneous aortic valve implantation (TAVI) , within the framework of the RHU STOP-AS and FHU CARNAVAL .
Cardiac research: Development and assessment of new treatments of diastolic dysfonction, chronic heart failure and acute cardiac decompensation, via pharmacological approaches or novel biotherapies for stimulation of cardiac angiogenesis and lymphangiogenesis. This research includes three ongoing ANR projects: POP-HEARTCITE-LYMPH and MiRAVALVE-CKD and one WinningNormandy MSCA co-fund project PROTECT. We also participate in cardiac-focused COST actions, such as EU-MetaHeart.